Detectable troponin levels predict poor prognosis in patients with left ventricular dysfunction undergoing internal defibrillator implantation

PACE - Pacing and Clinical Electrophysiology

Volumn 30, Issue 7, 2007, Pages 839-844

  Sonel, Ali F ^a   Shalaby, Alaa ^a,c   Mcconnell, Joseph P ^b   Czarnecki, Tammy ^a   Hogen, Scott ^b   Zahid, Maliha ^a   Amidi, Morteza ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b MAYO CLINIC   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiomyopathy; Implantable cardioverter defibrillator; Risk stratification; Troponins

Indexed keywords

CREATINE KINASE MB; TROPONIN T;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOMYOPATHY; COHORT ANALYSIS; CONTROLLED STUDY; DEFIBRILLATOR; FOLLOW UP; HEART DISEASE; HEART LEFT VENTRICLE DYSFUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTION; PREOPERATIVE PERIOD; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; CHI-SQUARE DISTRIBUTION; CREATINE KINASE, MB FORM; DEFIBRILLATORS, IMPLANTABLE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RISK ASSESSMENT; TROPONIN T; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34250715509     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2007.00770.x     Document Type: Article

References (31)

1. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002 346 : 877 883.
2. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004 350 : 2151 2158.
3. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, et al Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 352 : 225 237.
4. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, Greene HL, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000 21 : 2071 2078.
5. Sheldon R, O'Brien BJ, Blackhouse G, Goeree R, Mitchell B, Klein G, Roberts RS, et al. Effect of clinical risk stratification on cost-effectiveness of the implantable cardioverter-defibrillator: The Canadian implantable defibrillator study. Circulation 2001 104 : 1622 1626.
6. Krahn AD, Connolly SJ, Roberts RS, Gent M ATMA Investigators. Diminishing proportional risk of sudden death with advancing age: Implications for prevention of sudden death. Am Heart J 2004 147 : 837 840.
7. Gehi A, Haas D, Fuster V. Primary prophylaxis with the implantable cardioverter-defibrillator: The need for improved risk stratification. JAMA 2005 294 : 958 960.
8. Adams JE III., Bodor GS, Davilla-Roman VG, Delmez JA, Apple FS, Ladenson JH, Jaffe AS. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation 1993 88 : 101 106.
9. Missov E, Mair H. A novel biochemical approach to congestive heart failure: Cardiac troponin T. Am Heart J 1999 138 : 95 99.
10. Del Carlo CH, O'Connor CM. Cardiac troponins in congestive heart failure. Am Heart J 1999 138 : 453 466.
11. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997 96 : 2953 2958.
12. La Vecchia L, Mezzena G, Ometto R, Finocchi G, Bedogni F, Soffiati G, Vincenzi M. Detectable troponin I in patients with heart failure of nonmyocardial ischemic origin. Am J Cardiol 1997 80 : 88 90.
13. Setsuta K, Seino Y, Takanashi N, Ogawa T, Sasaki K, Harada A, Takano T, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol 1999 84 : 608 611.
14. La Vecchia L, Mezzena G, Zanolla L, Paccarano M, Varotto L, Bonanno C, Ometto R. Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. J Heart Lung Transplant 2000 19 : 644 652.
15. Setsuta K, Seino Y, Ogawa T, Arao M, Miyatake Y, Takano T. Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. Am J Med 2002 113 : 717 722.
16. Horwich TB, Patel J, MacLellan R, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003 108 : 833 838.
17. Mann DL, Bristow MR. Mechanisms and models in heart failure: The biomechanical model and beyond. Circulation 2005 111 : 2837 2849.
18. Olivetti G, Abbi R, Quanini F, Kajstura J, Cheng W, Nitahara JA, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med 1997 336 : 1131 1141.
19. Anversa P, Kajsture J. Myocyte cell death in the diseased heart. Circ Res 1998 82 : 1231 1233.
20. Logeart D, Beyne P, Cusson C, Tokmakova M, Leban M, Guiti C, Bourgoin P, et al. Evidence of cardiac myolysis in severe nonischemic heart failure and the potential role of increased wall strain. Am Heart J 2001 141 : 247 253.
21. Goto T, Takase H, Toriyama T, Sugiura T, Sato K, Ueda R, Dohi Y. Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure. Heart 2003 89 : 1303 1307.
22. Perna ER, Macin SM, Canella JP, Augier N, Stival JL, Cialzeta JR, Pitzus AE, et al. Ongoing myocardial injury in stable severe heart failure: Value of cardiac troponin T monitoring for high-risk patient identification. Circulation 2004 110 : 2376 2382.
23. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med 2005 353 : 1471 1480.
24. Buxton AE, Lee KL, DiCarlo L, Gold MR, Greer GS, Prystowsky EN, O'Toole MF, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 2000 342 : 1937 1945.
25. Wever EF, Hauer RN, Schrijvers G, van Capelle FJ, Tijssen JG, Crijns HJ, Algra A, et al. Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors. A randomized study. Circulation 1996 93 : 489 496.
26. Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA. Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. Am Heart J 2002 144 : 440 448.
27. Ishii J, Nomura M, Nakamura Y, Naruse H, Mori Y, Ishikawa T, Ando T, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol 2002 89 : 691 695.
28. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999 353 : 2001 2007.
29. Hurst TM, Hinrichs M, Breidenbach C, Katz N, Waldecker B. Detection of myocardial injury during transvenous implantation of automatic cardioverter-defibrillators. J Am Coll Cardiol 1999 34 : 402 408.
30. Schluter T, Baum H, Plewan A, Neumeier D. Effects of implantable cardioverter defibrillator implantation and shock application on biochemical markers of myocardial damage. Clin Chem 2001 47 : 459 63.
31. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995 333 : 77 82.